A recent study utilizing the TriNetX database reveals that shingles vaccination significantly lowers the risk of cardiovascular events in individuals aged 50 and older with atherosclerotic disease. The analysis, which included over 123,000 vaccinated individuals, found that those who received at least one dose of the Shingrix or Zostavax vaccine were 46% less likely to experience major adverse cardiac events and 66% less likely to die from any cause within a year of vaccination. Notably, the vaccinated cohort also showed a 32% reduction in heart attacks and a 25% decrease in strokes and heart failure.

These findings add to the growing body of evidence suggesting that late-life vaccination may confer unexpected health benefits beyond infectious disease prevention. The study highlights the importance of understanding the biological mechanisms behind these correlations, particularly the potential role of trained immunity in mitigating chronic inflammation associated with aging.

For longevity professionals, this underscores the therapeutic potential of vaccines like the shingles vaccine as a strategy for reducing cardiovascular risk in aging populations, warranting further investigation into their long-term impacts on healthspan.

Source: fightaging.org